Near-infrared upconversion-activated CRISPR-Cas9 system: A remote-controlled gene editing platform.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30949579.
- Also identified by DOI 10.1126/sciadv.aav7199 and PMC identifier 6447385.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As an RNA-guided nuclease, CRISPR-Cas9 offers facile and promising solutions to mediate genome modification with respect to versatility and high precision. However, spatiotemporal manipulation of CRISPR-Cas9 delivery remains a daunting challenge for robust effectuation of gene editing both in vitro and in vivo. Here, we designed a near-infrared (NIR) light-responsive nanocarrier of CRISPR-Cas9 for cancer therapeutics based on upconversion nanoparticles (UCNPs). The UCNPs served as "nanotransducers" that can convert NIR light (980 nm) into local ultraviolet light for the cleavage of photosensitive molecules, thereby resulting in on-demand release of CRISPR-Cas9. In addition, by preparing a single guide RNA targeting a tumor gene (<i>polo-like kinase-1</i>), our strategies have successfully inhibited the proliferation of tumor cell via NIR light-activated gene editing both in vitro and in vivo. Overall, this exogenously controlled method presents enormous potential for targeted gene editing in deep tissues and treatment of a myriad of diseases.
Medical subject headings
- CRISPR-Cas Systems
- Carcinoma, Squamous Cell
- Drug Carriers
- Gene Editing
- Infrared Rays
- Mouth Neoplasms
- Nanoparticles